SynthesisOncotarget2017
Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 6 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Risk factors for gastric cancer: an umbrella review of systematic reviews and meta-analyses.Frontiers in oncology · 2025Pooled it
- Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials.Frontiers in oncology · 2021Pooled it
- Aspirin and Its Potential Preventive Role in Cancer: An Umbrella Review.Frontiers in endocrinology · 2020Pooled it
- Aspirin use and pancreatic cancer risk: A systematic review of observational studies.Medicine · 2019Pooled it
- Guideline
- Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.BMC cancer · 2018Pooled it
- Beyond <italic>Helicobacter pylori</italic>: Current Insights into <italic>H. pylori</italic>-Naive Gastric Cancer.Digestion · 2026Review
- Article
- Expression of Salivary miRNAs, Clinical, and Demographic Features in the Early Detection of Gastric Cancer: A Statistical and Machine Learning Analysis.Journal of gastrointestinal cancer · 2024Article
- Article
- Risk Factors and Prevention of Stomach Cancer, ExcludingThe Korean journal of helicobacter and upper gastrointestinal research · 2024Review
- Deciphering gastric inflammation-induced tumorigenesis through multi-omics data and AI methods.Cancer biology & medicine · 2023Review
- Association between Dietary Inflammatory Index and Gastric Adenocarcinoma: A Multicenter Case-Control Study in Brazil.Nutrients · 2023Article
- Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention.Nature reviews. Clinical oncology · 2023Review
- Early Gastric Cancer: Update on Prevention, Diagnosis and Treatment.International journal of environmental research and public health · 2023Review
- Exposure to Commonly Used Drugs and the Risk of Gastric Cancer: An Umbrella Review of Meta-Analyses.Cancers · 2023Review
- Diet quality and risk of gastric adenocarcinoma: The Multiethnic Cohort.The American journal of clinical nutrition · 2023Article
- Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study.Cancer prevention research (Philadelphia, Pa.) · 2022Article
- Prediagnostic circulating inflammation-related biomarkers and gastric cancer: A case-cohort study in Japan.Cytokine · 2021Article
- Chemoprevention Against Gastric Cancer.Gastrointestinal endoscopy clinics of North America · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between non-steroidal anti-inflammatory drugs (NSAIDs) and gastric cancer (GC) risk is controversial. The aim of this study is to evaluate the chemopreventive effect of NSAIDs for GC.
methodsA literature search was performed for relevant studies using the PubMed and Embase database (up to March 2016). Risk ratios (RRs) and 95% confidence intervals (CIs) were used as the effect measures. The dose-response analysis and subgroup analysis were also performed.
resultsTwenty-four studies were included. Our results indicated that NSAIDs could reduce GC risk (any NSAIDs: RR=0.78, 96%CI=0.72-0.85; aspirin: RR=0.70, 95%CI=0.62-0.80; non-aspirin NSAIDs: RR=0.86, 95%CI=0.80-0.94), especially for non-cardia GC risk. Moreover, the dose-response analysis indicated the risk of GC decreased by 11% and 5% for 2 years increment of any NSAIDs and aspirin use, respectively. There were nonlinear relationships between the frequency of any NSAIDs use and aspirin use and GC risk (P for non-linearity<0.01), with a threshold effect of 5 times/week. A monotonically decreasing trend was observed only for the frequency of less than 5 times/week.
conclusionsOur results indicate that NSAIDs is inversely associated with GC risk, especially for non-cardia GC risk. NSAIDs use may become a feasible approach to prevent GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.